Search

everythinglearnresearchcommunity

for

Search:↓

Blocking JAK/STAT pathways can help treat hair loss from alopecia areata.

JAK inhibitors show promise in effectively treating hair loss from alopecia areata.

Tofacitinib helped some young children with severe hair loss grow their hair back without bad side effects.

Transepidermal drug delivery effectively treated areata alopecia with minimal side effects.

People with chronic Alopecia Areata often have lower vitamin D levels.

More research is needed to understand the genetic causes of Alopecia areata to develop better treatments.

Some women with PCOS have CYP21 mutations and IRS1 variants, but these genetic factors are not major contributors to PCOS.

The COVID-19 pandemic led to an increase in untreated hair diseases and showed the importance of teledermatology.

The document suggests using standardized methods to track and measure hair loss in alopecia areata, including patient self-assessment and a 50% improvement in specific scores as a treatment goal.

Topical calcipotriol may help treat alopecia areata, especially in those with low vitamin D.

PUVA treatment led to significant hair regrowth in over half of the patients with alopecia areata totalis and universalis.

Calcipotriol cream can effectively and safely treat mild-to-moderate patchy hair loss.

Oral JAK inhibitors are effective and safe for treating alopecia areata but may need ongoing use to keep results.

Alopecia areata severity and treatment response are linked to specific cytokine levels.

The Italian guidelines offer advice for diagnosing and treating alopecia areata based on expert opinion and limited clinical trial evidence.

People with Major Depressive Disorder have a higher chance of getting Alopecia Areata, and vice versa; antidepressants may lower this risk.

People with alopecia areata often have lower vitamin D levels and more inflammation, suggesting vitamin D might be involved in the condition.

Black and Hispanic women are more likely to have alopecia areata than white women.

Oral tofacitinib shows promise in treating atopic dermatitis and alopecia areata, but only slight improvement in vitiligo.

Narrowband UVB phototherapy alone is not very effective for treating alopecia areata.

Diphencyprone (DPC) is an effective and safe long-term treatment for alopecia areata, especially with maintenance therapy.

Hair loss in mice starts with immune cells damaging hair roots before it becomes visible.

Early diagnosis and treatment are crucial for preventing permanent hair loss in various scalp conditions, and while new treatments are promising, more research is needed to evaluate their effectiveness.

A substance called VIP might protect hair follicles from being attacked by the immune system, and problems with VIP signaling could lead to hair loss in alopecia areata.

Bimatoprost was found to be safer and more effective than mometasone furoate for treating scalp hair loss.

Intralesional steroids can help regrow hair in some alopecia areata patients but have side effects.

Certain HLA class II alleles increase or decrease the risk of alopecia areata.

Topical latanoprost doesn't effectively regrow hair in severe eyebrow alopecia areata cases.

Children with alopecia areata should only have thyroid screening if they have Down syndrome, a history of atopy, family history of thyroid disease, or signs of thyroid problems.

Oxidative stress may play a role in causing alopecia areata.